This bill creates a new chapter in Title 69 RCW (sections 1–5) that prohibits animal testing facilities, contract testing facilities, and manufacturers from using an animal test method in a drug development process when an alternative test method is available. It defines an "alternative test method" as a nonanimal method that provides equivalent or better scientific quality and relevance, has been identified by a validation body and adopted by the relevant federal agency or program, and does not use animals. The bill clarifies that nonanimal test methods are allowed, exempts situations where a federal regulatory authority requires an animal test method, and declares violations to be unfair or deceptive acts and unfair methods of competition under the consumer protection act (chapter 19.86 RCW). The measure sets out definitions for animal testing facilities, contract testing facilities, manufacturers, validation bodies, and links the terms "animal" and "drug" to external definitions in RCW 16.52.205 and 21 U.S.C. Sec. 321(g)(1), respectively. The extracted facts do not specify an effective date, do not provide enforcement mechanisms, penalties, or administrative procedures, and do not explain in detail how the availability of an "alternative test method" is to be determined beyond the definition requiring validation body identification and federal adoption.

If enacted, drug makers, testing labs (including private companies, state agencies, and universities), and contract testers would in practice have to stop using animal-based tests during drug development whenever a nonanimal test has been validated and adopted by the relevant federal regulator. That will likely shift their choices toward validated alternative methods when those methods exist, and it makes failing to switch a matter that can be pursued under Washington’s consumer protection law, so organizations face a new legal risk if they continue animal testing in those situations. Tests still required by a federal regulatory authority would remain allowed. Key implementation details are missing, so the real-world impact contains uncertainty: the bill text here does not say when it would take effect, how exactly “availability” of an alternative is determined beyond federal adoption and validation body identification, or what penalties or enforcement steps would follow consumer protection claims. The definitions of “animal” and “drug” rely on external statutes not included here, which could affect who and what products are covered.